Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma

Among patients who were MRD-negative at 10^-5 sensitivity after induction, the percentage with a premaintenance MRD-negative status at 10^-6 sensitivity was not significantly higher with ASCT than with Isa-KRd. Among patients who were MRD-positive status at 10^-5 sensitivity after induction, the percentage with a premaintenance MRD-negative status at 10^-6 sensitivity was not significantly higher with tandem ASCT than with single ASCT. (Funded by Intergroupe Francophone du Myélome and others; MIDAS ClinicalTrials.gov number, NCT04934475.).